For research use only. Not for therapeutic Use.
Trevogrumab（Cat No.:I042209）is a monoclonal antibody that targets and inhibits the PD-1 (programmed cell death protein 1) receptor on T-cells, a key immune checkpoint involved in suppressing the immune system. By blocking PD-1, trevogrumab aims to enhance T-cell activation and restore immune responses, allowing the body to better recognize and destroy cancer cells. It is being evaluated in clinical trials for its potential to treat various cancers, including solid tumors and hematologic malignancies. Trevogrumab is being studied for its safety, efficacy, and its ability to improve patient outcomes in cancer immunotherapy.
| Catalog Number | I042209 |
| CAS Number | 1429201-24-0 |
| Purity | ≥95% |
